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Development of passive CLARITY 
and immunofluorescent labelling 
of multiple proteins in human 
cerebellum: understanding 
mechanisms of neurodegeneration 
in mitochondrial disease
Jonathan Phillips1, Alex Laude2, Robert Lightowlers1,3, Chris M. Morris4, Doug M. Turnbull1 & 
Nichola Z. Lax1
CLARITY enables immunofluorescent labelling and imaging of large volumes of tissue to provide 
a better insight into the three dimensional relationship between cellular morphology and spatial 
interactions between different cell types. In the current study, we optimise passive CLARITY and 
immunofluorescent labelling of neurons and mitochondrial proteins in mouse and human brain tissues 
to gain further insights into mechanisms of neurodegeneration occurring in mitochondrial disease. 
This is the first study to utilise human cerebellum fixed in paraformaldehyde and cryoprotected in 
conjunction with formalin-fixed tissues opening up further avenues for use of archived tissue. We 
optimised hydrogel-embedding and passive clearance of lipids from both mouse (n = 5) and human 
(n = 9) cerebellum as well as developing an immunofluorescent protocol that consistently labels 
different neuronal domains as well as blood vessels. In addition to visualising large structures, we were 
able to visualise mitochondrial proteins in passively cleared tissues to reveal respiratory chain deficiency 
associated with mitochondrial disease. We also demonstrate multiple use of tissues by stripping 
antibodies and re-probing the cerebellum. This technique allows interrogation of large volumes 
intact brain samples for better understanding of the complex pathological changes taking place in 
mitochondrial disease.
One of the major goals of neurodegenerative research is to further understand the pathological processes 
underpinning neurological disease and to drive the development of treatment in the earliest stages of disease. 
Neurodegenerative research relies on the availability of human post mortem brain samples to characterise the 
neuropathological features using light-based imaging approaches including histochemical and molecular label-
ling methods. These approaches tend to focus on thin (5–20 μ m) sections of brain tissue and in these sections, it 
can be difficult to track individual neurons and their connections in a three dimensional (3D) volume using serial 
tissue sections. Recently, high resolution techniques, such as array tomography and serial block-face scanning 
electron microscopy, have been developed although these can be time consuming, technically difficult, expensive 
and restricted to small tissue volumes1,2. A major limitation associated with light based microscopy analysis of 
thicker sections stems from the fact that the CNS is heterogeneous giving rise to different refractive indices across 
the tissue, and also a high lipid content which can cause light scattering, restricting the ability to image thicker 
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sections. Multi-photon imaging overcomes this to a degree since it allows imaging of sections across hundreds of 
microns however it is not possible to image the entire brain.
A number of methods have focussed on addressing the problem of investigating thicker tissue sections 
with the aim of minimising the light scattering properties of tissue by either removing the lipids from the tis-
sue, or altering the refractive indices of tissue to make it more uniform, or a combination of the two. Clear 
Lipid-exchanged Acrylamide-hybridized Rigid Imaging compatible Tissue hYdrogel (CLARITY) is a new tech-
nique which allows interrogation of large volumes of tissues to reconstruct the 3D architecture of the brain and 
provide insights into abnormalities associated with neurodegeneration disease3. CLARITY works by allowing 
covalent binding of hydrogel monomers to primary amine groups of molecules within the tissue to form a hydro-
gel matrix, once formed the tissue is then subjected to lipid clearing methods while the structure remains intact 
and proteins, DNA and RNA are retained. The benefit of incorporating the native biological molecules into the 
hydrogel matrix is that there is negligible protein loss following the clearing step3,4. Once the clearing step has 
been completed, the tissue sections are then incubated in an imaging solution to further change the refractive 
index of the tissue and reduce light scattering. The technique produces transparent tissue on a large-scale and as 
the hydrogel is porous, it allows the diffusion of antibodies during immunostaining protocols on both mouse and 
human tissue.
In light of recent papers utilising CLARITY to investigate neuronal changes in human tissue with neurological 
disorders such as Alzheimer’s disease5, Parkinson’s disease6 and autism3, we aimed to optimise the technique to 
enable the investigation of pathological changes which frequently occur in the cerebellum of patients with mito-
chondrial disease. Cerebellar ataxia is commonly reported in mitochondrial disease and neuropathological find-
ings report microinfarcts, Purkinje cell loss, axonal torpedoes and mitochondrial respiratory chain defects7,8. The 
cerebellum has a well-defined circuitry receiving glutamatergic innervation from the climbing fibres and mossy 
fibres which synapse on Purkinje cells. The Purkinje cells are sandwiched between the molecular and granular 
cell layers in the cerebellar cortex and project their GABAergic axons into the deep cerebellar nuclei. There have 
been a number of studies documenting Purkinje cell abnormalities in mitochondrial disease. Therefore in this 
study we adopt an integrative approach to understand the impact of mitochondrial defects on the 3D cerebellar 
circuitry using CLARITY. We report the development of an improved passive CLARITY technique, quadruple 
immunofluorescent staining using multiple markers and confocal microscopy imaging of human post-mortem 
cerebellum.
Results
We first report the optimal methods for passively clearing 4% paraformaldehyde (PFA)-fixed mouse cerebellum 
before applying this to formalin-fixed human cerebellum tissues since these are a limited and valuable resource. 
We describe the ideal conditions to perform immunofluorescent labelling of neurons, their connections and 
mitochondrial proteins using various antibodies to further understanding of cerebellum connectivity in normal 
and pathological conditions.
Mouse Cerebellum. To optimise hydrogel embedding of brain tissue, we used pre-sectioned and whole cer-
ebellum from five wild type 12 month old C57/Bl6 mice. Following 3 days of hydrogel incubation at 4 °C, samples 
were transferred to a 37 °C water bath to initiate polymerisation. After 4 hours, the hydrogel polymerised forming 
a strong hydrogel matrix around the tissue. Excision of the tissue from excess hydrogel matrix was straightfor-
ward for the whole cerebellum while the pre-sectioned cerebellum was easily damaged. Therefore, for further pro-
cessing only whole cerebellum samples were embedded in hydrogel, polymerised and then sectioned at various 
section thickness (250–500 μ m) using a vibratome.
A number of recent studies have identified issues with electrophoretic-based active clearance techniques and 
resultant tissue damage9,10. Given this and the recent success of passive clearance techniques4,11, we chose to use a 
passive clearing approach. Mouse cerebellum of variable section thickness was rendered transparent by incuba-
tion in clearing buffer at 37 °C for 7 days (Fig. 1a). There was a noticeable increase in tissue expansion following 
passive incubation in the clearing solution which is visible in Fig. 1a. This has been previously reported by others 
using both passive and active clearing processes and is resolved once samples are immersed in mounting solution 
prior to imaging without negative effects on the cellular morphology or protein content3,4.
Optimisation of immunofluorescent protocol on passively cleared 250 μm mouse cerebellum 
sections. The original study by Chung et al. utilised a staining protocol whereby primary and secondary anti-
bodies were diluted in sodium borate (SB) buffer and incubated at 37 °C for 24 hours each, with 12 hour washes 
in between3. To test this method, we used an antibody to label neurons and their processes (anti-neurofilament 
H 200 kDa (NF-H)), myelin (anti-myelin basic protein (MBP)) and mitochondria (anti-porin) since these anti-
bodies are consistently reliable in 5 μ m sections (Supplementary Figure 1). Replicating Chung and colleagues 
approach, we found that using cleared sections of 250 μ m thickness and incubating with antibodies diluted in SB 
buffer at 37 °C for 24 hours produced only weak staining for neurofilament H, and an almost total lack of staining 
was observed for myelin basic proteins and porin (Fig. 1b). To improve immunofluorescent labelling, we reduced 
the temperature to 4 °C since a lower temperature increases the specificity of antibody binding and increased the 
length of incubation to 6 days for the primary antibodies and 4 days for the secondary antibodies. In this trial, we 
compared the use of SB buffer and PBS with 0.1% tween-20 (PBST) as a diluent. Both SB buffer (Fig. 1c) and PBST 
(Fig. 1d) at the lower temperature with extended incubation periods produced specific staining of mitochondria, 
neurons and axons and myelin. However, the SB buffer formed crystals both in the solution and on the sections at 
this lower temperature. Therefore we used primary antibodies diluted in PBST and incubated with tissue at 4 °C 
for 6 days following by extensive washing and diluting secondary antibodies in PBST at 4 °C for 4 days for immu-
nofluorescent staining on mouse sections. To confirm the necessity of clearing we stained an unclear section 
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Figure 1. Demonstration of passive CLARITY and optimisation of immunofluorescent labelling 
conditions on wild type mouse brain sections. Representative images of wild type 12 month old C57/
Bl6 mouse cerebellar sections of varying thickness are shown pre- and post-passive clearance (a). Passively 
cleared cerebellar sections were immunofluorescently labelled with antibodies raised against porin (green), 
neurofilament H (NF-H; red) and myelin basic protein (MBP; purple). Various conditions were tested for the 
immunolabelling protocol; (b) sodium borate buffer at 37 °C for 24 hours, (c) sodium borate buffer at 4 °C for 
6 days for the primary antibodies, then at 4 °C for 4 days for secondary antibodies, (d) PBST at 4 °C for 6 days 
for the primary antibodies, then at 4 °C for 4 days for secondary antibodies and (e) The advantages of passively 
clearing tissue sections is exemplified in an uncleared section which was stained using the protocol in (d). Scale: 
100 μ m.
www.nature.com/scientificreports/
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using the 4 °C prolonged incubation step (Fig. 1e) which revealed weak staining of myelin and absent labelling of 
mitochondria or neurons.
Poor antibody penetration in passively cleared mouse cerebellar sections. Confocal imaging of 
immunofluorescently labelled sections at different thicknesses revealed issues with antibody penetration which 
was notably reduced above 300 μ m (Supplementary Figure 2). The initial and final z stacks to 150 μ m within the 
sections revealed strong and uniform staining that decreased dramatically towards the middle of the section. Poor 
antibody penetration has been observed previously in a study by Ando et al.5. To improve permeability of the 
tissue, we tested pre-treatment of the tissues in PBS-Triton X and proteinase K (10 mg/ml) solution for 10 min-
utes12, however proteinase K treatment caused the tissue to disintegrate and minimal improvement was seen with 
PBS-Triton X. Therefore the remainder of the study was conducted using 250 μ m thick sections.
Optimisation of reliable antibodies in mouse tissue. The outlined immunostaining method demon-
strates labelling of neurons, myelin and mitochondria in the cerebellar cortex however we now wanted to con-
firm that it is possible to label other components of the cerebellum (Fig. 2). To specifically visualise Purkinje cell 
bodies, we labelled calbindin (anti-calbindin D-28k) and parvalbumin (anti-parvalbumin) since they are both 
calcium binding proteins expressed in cerebellar Purkinje cells. Both antibodies produced specific labelling of the 
Purkinje cell bodies (Fig. 2a,b, white arrows) with calbindin also labelling the dendrites of Purkinje cells (Fig. 2a, 
white arrow head). To document changes in Purkinje cell connectivity, Purkinje cell axons were labelled with 
NF-H (Fig. 2c, white arrow) and phosphorylated neurofilaments (Fig. 2d, white arrows) to observe Purkinje cell 
axons projecting from the Purkinje cell layer through the granular cell layer to the deep white matter. The myelin 
sheath surrounding Purkinje cell axons in the granule cell layer can also be visualised through the labelling of 
MBP (Fig. 2e, white arrowhead). To visualise mitochondria, antibodies raised against an outer membrane pro-
tein, porin (anti-porin) and a subunit of the mitochondrial respiratory chain complexes, complex IV subunit I 
(anti-COXI) were used and showed positive immunoreactivity (Fig. 2f). All optimal antibody conditions are 
given in Table 1.
Human Cerebellar sections. We applied our optimised method on human cerebellum in order to visualise 
connections within control individuals (n = 2) and patients with clinically and genetically confirmed mitochon-
drial disease (n = 5). The human cerebellum sections required longer incubation in clearing solution in order to 
become transparent, with tissues taking at least four weeks to clear (Fig. 3a). The length of clearing is imperative 
for the quality of staining achieved, since sections that were only cleared for 2 weeks revealed weak staining of 
Figure 2. Representative images of immunofluorescent labelling of neurons, axons and mitochondrial 
proteins in passively cleared 250μm mouse cerebellum. Passively cleared 250 μ m wild type mouse cerebellum 
sections were stained for both neuronal and mitochondrial proteins commonly found in the cerebellum. 
Calbindin ((a); red; 546 nm) and parvalbumin ((b); purple; 647 nm) antibodies positively label Purkinje cell 
bodies. Purkinje cell axons were visualised through positive labelling of neurofilaments ((c); red; 546 nm; NF-H, 
and (d); red; 546 nm; SMI-31) and myelin ((e); purple; 647 nm; MBP). Mitochondria were detected through 
positive labelling of COXI protein ((f); purple; 647 nm; COXI). Scale bar: 100 μ m.
www.nature.com/scientificreports/
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the three markers that were applied (anti-COXI, anti-NF-H and anti-MBP; Fig. 3b). Only a small proportion of 
the myelin sheath was labelled while a limited number of axons were also labelled. However when the length of 
passive clearing was extended to four weeks, there was extensive labelling of the myelin sheath in the granule cell 
layer, clear labelling of mitochondria in the Purkinje cell soma and a higher density of axons (Fig. 3b).
Anti-COXI, anti-NF-H and anti- MBP were applied to the passively cleared 250 μ m human cerebellar sections 
using PBST as the diluent at 4 °C and were incubated for 6 days and 4 days for the primary and secondary anti-
bodies, respectively. From the seven cases, there were mixed results. There was positive labelling of both NF-H 
and MBP allowing for the visualisation of myelinated Purkinje cell axons in the granule cell layer of control 1 
and Patients 2, 4 and 5 (Fig. 3c). While in the case of control 2, patient 1 and 6 there was no specific staining 
of any antibody. We are unsure why staining of these tissues was not successful since the length of fixation and 
post-mortem interval (PMI) of control 2 (fixation: 8 years, PMI: 39 hours), patient 1 (fixation: 6 years, PMI: 
21 hours) and 6 (fixation: 2 years, PMI: 76 hours) falls within the range of successful cases (the only exception 
being control 2 where fixation 1 year over this range) (fixation: 3–7 years, PMI: 21–112 hours). Control 2 demon-
strated non-specific staining of the blood vessels and aggregation of the fluorophores in the 488 nm channel. 
There was some specific staining of both NF-H and MBP in Patient 3, however it was only the larger thicker axons 
that were labelled.
The human sections that have been used in this study were fixed in formalin for a maximum length of seven 
years while in other studies tissues were fixed for six years3,5,6. In addition to formalin-fixed sections, Liu and col-
leagues applied the CLARITY protocol to fresh brain tissue and found that fresh cortical sections took a shorter 
amount of time to passively clear (~40 days) compared to formalin-fixed cortical sections (~60 days). On the 
basis of the success in fresh tissue and the availability of human tissue that had been fixed in PFA then frozen at 
the NBTR, we applied the CLARITY protocol to human cerebellar sections that had been PFA-fixed then frozen 
rather than archival formalin-fixed sections. The PFA-fixed and frozen section (control 3) passively cleared in 6 
days and there was positive staining of NF-H in the sections (Supplementary Figure 3) confirming that in addi-
tion to formalin-fixed sections, PFA-frozen sections are also a useful resource.
Imaging of structures in the passively cleared human cerebellum sections. Since we were able 
to visualise Purkinje cells and mitochondria in human cerebellar sections, we performed immunofluorescent 
staining and confocal microscopy on passively cleared human sections (250 μ m) to visualise a variety of different 
cellular domains including dendrites, axons and the vascular network (Fig. 3d). Anti-NF-H was used to label the 
Purkinje cells and their dendrites (Fig. 3d) while both anti-NF-H and anti-MBP, label myelinated axons (Fig. 3d). 
Confocal images were reconstructed into 3D stacks allowing for the visualisation of the intricate processes of both 
structures. To visualise the blood vessels, anti-α smooth muscle actin and anti-glut-1 were used as markers for 
smooth muscle cells and endothelium respectively (Fig. 3d). Through labelling glut-1, capillaries were observed 
throughout the 250 μ m thick section and co-localisation of glut-1 and α smooth muscle actin was observed in 
arterioles. The 3D morphology was reconstructed using Imaris software (Supplementary video 1).
Visualisation of mitochondria in passively cleared human cerebellum sections. Following 
the success of visualising large structures such as axons, dendrites and the vascular network in both control 
Primary Antibody Target Host Isotype Dilution
Manufacturer and product 
code Quality of Staining
anti-Neurofilament H 200 kDa Neurofilament H (200 kDa) Rabbit IgG 1:200 Millipore (AB5539) Specific labelling of axons
Anti-Myelin basic protein Myelin basic protein Mouse IgG1 1:500 Biolegend (836502) Specific labelling of myelin
anti-NDUFA13 NDUFA13 Mouse IgG2b 1:100 Abcam (ab110240) Specific positive staining of mitochondria
Anti-Porin Porin Mouse IgG2b 1:100 Abcam (ab14734) Specific positive staining of mitochondria
Anti-complex IV subunit I COX1 Mouse IgG2a 1:100 Abcam (ab14705) Specific positive staining of mitochondria
anti-complex IV subunit IV COX4 Mouse IgG2a 1:100 Abcam (ab14744) Specific positive staining of mitochondria
anti-SMI-31 Phosphorylated neurofilament H & M Mouse IgG1 1:1000 Biolegend (801601) Specific labelling of axons
anti-SDHA
Succinate 
dehydrogenase 
complex, Subunit A 
(complex II)
Mouse IgG1 1:100 Abcam (ab14715) Specific positive staining of mitochondria
anti-parvalbumin Parvalbumin Mouse IgG1 1:100 Swant (235) Specific labelling of Purkinje Cell soma
anti-calbindin D-28k Calbindin Mouse IgG1 1:100 Swant (235) Specific labelling of Purkinje Cell soma
Anti-glut-1 Endothelial cells Rabbit IgG 1:100 Thermofisher (PA1–21401) Staining of both arterioles and capillaries
Anti-α smooth muscle actin Smooth muscle cells Mouse IgG2a 1:100 Dako (M8051)
In formalin-fixed sections, the smooth 
muscle layer in arterioles are clearly labelled 
but there is non-specific staining of nuclei. 
This non-specific staining is not observed 
in the 4% PFA-fixed and sucrose frozen 
section. 
Table 1.  Details of the primary antibodies trialled on 250 μm mouse cerebellar sections and summary of 
the results. The details of primary antibodies that are commonly used in our laboratory and a summary of the 
results when applied 250 μ m thick mouse cerebellar sections that have been passively cleared.
www.nature.com/scientificreports/
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individuals and patients with mitochondrial disease, we then sought to determine if it was possible to visualise 
mitochondrial respiratory chain proteins in passively cleared cerebellar sections for the purpose of defining mito-
chondrial respiratory chain deficiency.
Previous studies have used a mitochondrial mass marker in combination with a complex I antibody to 
determine if there is downregulation of complex I expression, a sign of respiratory chain deficiency in mito-
chondria13,14. In passively cleared control sections, complex I subunits NDUFB8 and NDUFA13 were tested in 
conjunction with the mitochondrial mass markers, porin and SDHA (for complex II). There was positive staining 
of all the mitochondrial antibodies with both NDUFB8 and NDUFA13 co-localising with their respective mito-
chondrial mass markers, thereby confirming positive and specific staining of complex I subunits (Fig. 4a). The 
neuronal marker NF-H was used as positive control to confirm that the immunolabelling protocol was successful.
After the successful labelling of mitochondrial proteins, we then compared respiratory chain deficiency in 
passively cleared cerebellar sections from patients with mitochondrial disease and control subjects. Cerebellar 
sections from control 1, control 2, patient 2 (m.8344 A > G) and patient 4 (POLG) were stained for NF-H (to 
serve as a neuronal marker), NDUFB8 (complex I marker) and Porin (mitochondrial mass marker; Fig. 4b). Only 
these sections were used for this optimisation step since they consistently produced the best results following each 
round of immunolabelling. In control sections there is co-localisation between NDUFB8 and porin confirming 
that there is no respiratory chain deficiency. In both patients there is a clear and global loss of NDUFB8 relative to 
porin which confirms respiratory chain deficiency in patients. The loss of NDUFB8 labelling compared to porin 
confirms that it is possible to visualise respiratory chain deficiency in mitochondria within multiple neuronal 
Figure 3. Demonstration of passive CLARITY and immunofluorescent labelling of different neuronal 
subcompartments, blood vessels and mitochondria. 250 μ m human cerebellar sections from control 
individuals and a patient with mitochondrial disease underwent passive clearing at 37 °C for 4 weeks (a). The 
quality of immunofluorescent staining is determined by duration of passive clearing; 2 weeks of passive clearing 
produced minimal labelling of the white matter in the granule cell layer (NF-H; green; 488 nm and MBP; red, 
546 nm) with an absence of labelling of mitochondria (COXI; purple; 647 nm; (b)). Extending passive clearing 
to 4 weeks improved the quality of stain with identifiable Purkinje cells and their axons (NF-H, green; 488 nm) 
and their myelin sheaths (MBP; red, 546 nm) and mitochondria (COXI; purple; 647 nm; (b)). In cerebellum 
subjected to passive clearing for four weeks, positive labelling of mitochondria (COXI; purple; 647 nm) and 
myelinated Purkinje cell axons (NF-H; green; 488 nm and MBP; red; 546 nm) were identified post-mortem 
human cerebellum tissue from controls and patients with mitochondrial disease (c). Using a combination of 
antibodies, it is possible to label neurons and track their three dimensional projections, including Purkinje cell 
(NF-H), axons (NF-H and MBP) and their dendritic arborisations (NF-H; (d)). It is also possible to detect the 
vascular network (Glut-1 and α -smooth muscle actin; (d)). Scale: 100 μ m.
www.nature.com/scientificreports/
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subcompartments within passively cleared sections and importantly allow documentation of the distribution of 
respiratory chain deficiency within individual neurons, their dendrites and axons.
Quadruple immunofluorescent staining in passively cleared human cerebellum sections. 
Previous studies investigating mitochondrial respiratory chain abnormalities in post-mortem brain tissue have 
focused on immunofluorescent staining on thin sections14, which are limited by the amount of information that 
can be captured about neurons and their projections. Using 250 μ m clarified patient cerebellum, we tested the 
feasibility of quadruple immunofluorescent assessment of mitochondrial respiratory chain complex I and mito-
chondrial mass in neurons and their associated myelinated axons. In order to achieve this we used two mito-
chondrial markers; a marker for a subunit of complex I (NDUFA13) and a marker for nuclear-encoded complex 
IV (COX4) for mitochondrial mass and then NF-H and MBP to identify neurons and their myelinated axons 
(Fig. 5). The secondary antibodies used were conjugated to different fluorophores including Alexa-405 nm (for 
NF-H), Alexa-488 nm (for COX4), Alexa-546 nm (for NDUFA13) and Alexa-647 nm (for MBP) to allow spectral 
distinction of the different proteins, and this was the first time that the 405 nm fluorophore had been used on a 
passively cleared piece of tissue. The results from the best cases are depicted in Fig. 5, with the specific staining of 
the intricate network of myelinated axons clearly visible; COX4 and NDUFA13, positively labelled complex I and 
IV in mitochondria in the granule cell layer and Purkinje cell soma showing good colocalisation in control 1. In 
patient tissues, both patient 2 (m.8344 A > G) and patient 3 (POLG) had a similar expression of NDUFA13 com-
pared to COX4 while patient 4 (POLG), the expression of NDUFA13 in the Purkinje cell bodies appears reduced 
compared to COX4. These observations are in agreement with a previous study by Chrysostomou and colleagues 
that used immunofluorescence in thin sections to investigate respiratory chain deficiency13.
However, there is a high level of autofluorescence in the 405 nm channel, confirmed by no primary control, 
making it difficult to visualise NF-H staining. In these sections, there is a high level of background noise and 
blood vessels are clearly visible (white arrow) in the 405 nm channels.
Reusing previously stained passively cleared human cerebellar sections. As the native proteins 
are incorporated into the hydrogel, a proposed advantage of the CLARITY method, is the ability to reuse stained 
cleared sections3. Therefore there would be a reduced risk of protein loss when using a detergent to strip away the 
old antibodies.
A section that had been previously stained and imaged with α -smooth muscle actin, NF-H and glut-1 anti-
bodies (Fig. 6a) underwent a second step of clearing at 37 °C for one week. Once the clearing step was completed, 
the section was imaged to confirm that none of the previous staining was present. There was no labelling of 
α -smooth muscle actin, NF-H or glut-1 in the newly cleared section (Fig. 6b). The section was re-stained with 
COX1, NF-H and MBP. Imaging of this section show labelling of the axons and myelin sheath (Fig. 6c). No blood 
vessels were visible confirming that the previous staining had been completely removed and that there was no 
protein loss as there was successful staining in the second round.
All optimal conditions for primary and secondary antibodies used on passively cleared human tissues are 
given in Supplementary Table 1 and Supplementary Table 2, respectively.
Discussion
In conclusion we have shown successful passive clearing of both fresh and fixed mouse sections as well as archival 
formalin-fixed human tissue sections from both control individuals and patients with mitochondrial disease. 
We have also demonstrated for the first time that PFA-fixed cryoprotected frozen human cerebellar sections are 
suitable samples for CLARITY which increases access to and analysis of archived material. Using passively cleared 
sections, we trialled a number of immunolabelling conditions starting with previously published methods3, and 
observed that our protocol of using PBST as a diluent with prolonged antibody incubations at 4 °C gave optimal 
staining. The optimal conditions for all antibodies used in this study are summarised in Table 1. Using these 
antibodies, we were able to visualise dendrites, axons, Purkinje cell bodies and the vasculature network within the 
cerebellum. In addition to those large structures, for the first time, we were able to image mitochondrial proteins 
in passively cleared cerebellum and were able to detect respiratory chain deficiency in patients with mitochondrial 
disease. The respiratory chain deficiency observed agrees with previous reports in the same individuals further 
validating this approach13. The ability to image mitochondrial proteins in passively cleared volumes of tissues will 
advance understanding of the distribution of mitochondrial respiratory chain deficiency in different compart-
ments of the same neuron and provide both spatial and structural information about those affected cells. This will 
allow us to ask and answer questions about where respiratory chain deficiency develops first in the neuron, and 
how this compares to other neighbouring cells in the brain.
We have also made the first attempt to quadruple stain passively cleared sections, however our efforts are not 
without complication as there is a high level of autofluorescence in the 405 nm channel which cannot be circum-
vented by glycerine treatment. One of the major advantages of CLARITY is the ability to reuse multiple tissue 
volumes that have previously undergone immunofluorescent staining3. Replication of these findings has not been 
reported, however we confirmed that a seven day incubation in the clearing solution was sufficient to remove 
all antibodies and subsequent to the clearing process, positive labelling of different structures is made possible. 
This property of CLARITY is highly valuable since it allows for the reuse of a rare resource such as post-mortem 
human sections from individuals with a rare disorder such as mitochondrial disease, and could allow reconstruc-
tion of the same piece of tissue with different cellular or organelle markers.
The combination of CLARITY and our immunolabelling protocol will open new avenues into the neuropatho-
logical research of mitochondrial disease. CLARITY will enable exploration of the global changes to Purkinje 
cell connectivity and how mitochondrial dysfunction might contribute to an irreversible loss of Purkinje cells. 
Additionally we will be able to look at the complex vascular structure in both non-lesioned and lesioned regions 
www.nature.com/scientificreports/
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Figure 4. Assessment of mitochondrial respiratory chain deficiency in Purkinje cell neurons in human 
cerebellum. 250 μ m-thick cerebellum section were passively cleared and immunofluorescently labelled to 
identify mitochondrial mass (porin and SDHA, 647 nm) and complex I subunits within the mitochondrial 
respiratory chain (NDUFB8 and NDUFA13; 546 nm) in conjunction with a neuronal marker (NF-H; 488 nm) 
in control 1 (a). To interrogate respiratory chain deficiency (reduced abundance of a complex I subunit 
relative to mitochondrial mass) in Purkinje cells and their projections in patients with mitochondrial disease 
neurons (NF-H; 488 nm), mitochondria (porin; 647 nm) and complex I subunit (NDUFB8; 546 nm) were 
immunofluorescently labelled. Control Purkinje cells reveal matched abundance of NDUFB8 protein relative 
to porin protein (control 1 and 2), while patient Purkinje cells and surrounding neurons showed an absence of 
NDUFB8 protein relative to porin protein level confirming the presence of complex I deficient mitochondria in 
these cells (patient 2 and 4; (b)). Scale: 100 μ m.
www.nature.com/scientificreports/
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of patients with mitochondrial disease and compare these with control individuals to help determine vasogenic 
factors in the formation of focal necrotic lesions which are common in patients with mitochondrial disease. This 
will not only benefit neuropathology of mitochondrial disease but also common neurodegenerative disorders, as 
already shown5,6, as it will allow for the investigation of global changes to vascular, dendritic or axonal networks 
in sections to provide insight to how the neuronal population reacts to a degenerative stimuli.
Methods
Mice. Five wild type 12 month old C57BL/6 mice were used in the study. Mice were culled using cervical 
dislocation. The brains were then excised and incubated in 4% PFA at 4 °C overnight and then washed in PBST. 
All animal experimental procedures were conducted in accordance with the guidelines of the UK Home Office 
guidelines and under its approval (licence 60/4455).
Figure 5. Representative images of Purkinje cells and their myelinated axons in human cerebellum 
following quadruple immunofluorescence. Passively cleared 250 μ m thick human cerebellar sections were 
stained for neurofilament H (blue), NDUFA13 (red), COX4 (green) and Myelin basic protein (purple). 
Mitochondria are clearly visible through the positive labelling of NDUFA13 (red) and COX4 (green). The 
myelin sheaths (Myelin basic protein, 647) of the Purkinje cell axons have been clearly labelled. In the 
405 nm channel there is a high level of autofluorescence making it difficult to visualise Purkinje cell axons 
(neurofilament H). The presence of autofluorescence in the 405 nm and 488 nm channel was confirmed through 
a no primary antibody control section. Scale: 100 μ m.
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Human tissue. Formalin-fixed cerebellar brain tissue was obtained from six patients (age range: 55–79 years) 
with genetically and clinically confirmed mitochondrial disease, and two control individual (age: 72 years and 
77 years) with no clinical or pathological evidence of neurological disease (see Table 2). A PFA-fixed and fro-
zen control section with no clinical or pathological evidence of neurological disease was also used in this study 
(Control 3). The tissue was obtained through the Newcastle Brain Tissue Resource (NBTR) and sections (~3 cm 
width) containing at least two cerebellar folia were removed from large fixed cerebellum sections. The sections 
were washed in PBST at 4 °C overnight. The study was approved by Newcastle and North Tyneside Local Research 
Ethics Committee. All human material were used in accordance with the Declaration of Helsinki. The Newcastle 
Brain Tissue Resource is covered by the Newcastle University Human Tissue Authority license as a research tissue 
bank. All tissue was collected with informed consent.
Hydrogel Preparation. The hydrogel solution was prepared by combining 20 ml of acrylamide (40%, 
Bio-Rad Laboratories), 10 ml bis-acrylamide (2%, Bio-Rad Laboratories), 1 g VA-044 initiator (0.25% w/v, Alpha 
Laboratories), 40 ml 10 X PBS and 310 ml dH2O. This was completed on ice and then stored at − 20 °C until 
needed.
Tissue embedding. The tissue was placed in 50 ml of hydrogel solution and incubated for 3 days (mice) or 
7 days (human) at 4 °C. Once the incubation was completed, the Falcon tubes were opened and placed in a desic-
cation chamber where it was filled with nitrogen for 10 minutes. A vacuum pump then removed all gas from the 
desiccation chamber for 10 minutes before being refilled with nitrogen from a tank for another 10 minutes. The 
Falcon tubes were resealed ensuring exposure to the atmosphere was minimal. The Falcon tubes were transferred 
to a 37 °C water bath for 3 hours to initiate the polymerisation of the hydrogel.
Passive Tissue Clearing. Once the hydrogel had polymerised, the tissue was removed in a fume hood. The 
tissue was washed in PBS overnight and then sectioned to 250 μ m on a vibratome. The clearing solution was pre-
pared by combining 24.722 g boric acid (Sigma Aldrich), 80 g sodium dodecyl sulphate (Sigma Aldrich), and 2ltr 
dH2O and pH adjusted to 8.5 by adding NaOH. The 250 μ m sections were placed in a 50 ml Falcon tube and filled 
with 40 ml clearing solution before being placed in a 37 °C water bath. The clearing solution was changed every 
other day. The length of time for passive clearing was assessed by eye but for mouse 250 μ m cerebellar sections 
typically cleared in 7 days while for human 250 μ m cerebellar sections it was > 4 weeks.
Immunofluorescent staining. Once clearing was comple, the sections were washed with PBS five times for 
30 minutes and kept in PBS at 4 °C until required. The sections were then incubated in normal goat serum (10% 
Figure 6. Reusing passively cleared and stained 250 μm thick control human cerebellum sections. Passively 
cleared sections were originally stained for α -smooth muscle actin (purple; 647 nm), neurofilament H (green; 
488 nm) and Glut-1 (red; 546 nm) producing a clear image of the cerebellar vascular network (a). Following 
a week long incubation in the clearing solution, the antibodies were removed and the sections were then 
successfully stained with COX1 (purple; 647 nm), neurofilament H (green; 488 nm) and myelin basic protein 
(red; 546 nm) demonstrating the distribution of mitochondria in myelinated axons (b). Scale: 100 μ m.
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v/v, Sigma Aldrich) for 90 minutes to block non-specific binding of secondary antibodies. The properties of the 
antibodies used in the study are summarised in Supplementary Table 2.
For labelling of mitochondrial proteins, the markers of respiratory chain deficiency (NDUFB8 and 
NDUFA13) were biotinylated. The immunolabelling protocol consisted of a 6 day incubation of primary antibod-
ies (NDUFB8, Porin and Neurofilament H or NDUFA13, SDHA and Neurofilament H) in PBS at 4 °C then a 4 day 
incubation with the biotin conjugated secondary antibodies (Anti-Mouse IgG, Fcγ Subclass 1 biotin conjugate or 
Anti-Mouse IgG, Fcγ Subclass 2b biotin conjugate) at 4 °C. Finally the fluorophores (Streptavidin, Alexa Fluor 546 
conjugate, Alexa Fluor 647 anti-mouse IgG2b and Alexa Fluor 488 anti-rabbit IgG or Streptavidin or, Alexa Fluor 
546 conjugate, Alexa Fluor 647 anti-mouse IgG1 and Alexa Fluor 488 anti-rabbit IgG) were applied for 4 days at 
4 °C before processing for imaging.
Imaging. In preparation for imaging, cerebellar sections were washed 5 × 30 minutes in PBS before a 30 min-
ute incubation in 0.2 M glycine and an overnight incubation in Refractive Index Matching Solution (RIMS, 40 g 
Histodenze (Sigma Aldrich), 30 ml Phosphate Buffer (0.62 g Sodium dihydrogen phosphate 2.18 g Sodium hydro-
gen phosphate 1 L dH2O pH 7.4), 0.1% tween-20 (Sigma Aldrich)). For the purpose of imaging the sections were 
placed between two coverslips. Cerebellar sections were imaged (Z-stack volume, 250 μ m) with an X20 objective 
(0.70 numerical aperture) on a confocal laser microscope (Nikon A1R, Nikon instruments) using the Galvano 
settings at excitation wavelengths of 488 nm, 546 nm and 647 nm. NIS Elements viewer software (Nikon instru-
ments) was used to view the images post capture while Imaris software (Bitplane) was used for the 3D rendering 
modifications.
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 Gender
Age 
(Years)
PMI 
(Hours)
Formalin-fixed/
PFA-sucrose frozen
Fixation 
(years) Genetic defect Cause of Death Publications
Control 1 F 72 27 Formalin-fixed 7 NA Pulmonary oedema.
Control 2 F 58 39 Formalin-fixed 8 NA Cushing’s disease.
Control 3 M 65 28 PFA-sucrose frozen 15 weeks NA
Respiratory failure 
due to acute bronchial 
asthma.
Patient 1 M 30 21 Formalin-fixed 6 m.3243 A > G Left ventricular failure. 13,14
Patient 2 M 58 66 Formalin-fixed 3 m.8344 A > G Stroke-like episode. 13,14
Patient 3 M 79 85 Formalin-fixed 4
POLG 
(p.Thr251Ile/p.
Pro587Leu; 
p.Ala467Thr)
Pneumonia due to 
mitochondrial disease. 13,14
Patient 4 M 55 112 Formalin-fixed 3
POLG 
(p.Trp748Ser 
and 
p.Arg1096Cys)
Complications due to 
mitochondrial disease. 13,14
Patient 5 F 60 39 Formalin-fixed 4
Multiple mtDNA 
deletions due to 
an unconfirmed 
nDNA defect
Pulmonary embolus.
Patient 6 M 47 76 Formalin-fixed 2 m.3243 A > G Cardiac arrest.
Table 2.  Tissue details for the control subjects and patients with mitochondrial disease that are used in 
this study. The details which include age, gender, Post mortem interval (PMI), fixation length and cause of 
death from tissue that was supplied by NBTR. NA – Not applicable.
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